Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Non-steroidal anti-inflammatory drugs and risk of heart failure exacerbation: A systematic review and meta-analysis
Authors: Patompong Ungprasert
Narat Srivali
Wonngarm Kittanamongkolchai
Mayo Clinic
Mahidol University
Keywords: Medicine
Issue Date: 1-Jan-2015
Citation: European Journal of Internal Medicine. Vol.26, No.9 (2015), 685-690
Abstract: © 2015 European Federation of Internal Medicine. Background The association between exacerbation of heart failure (HF) and use of non-steroidal anti-inflammatory drugs (NSAIDs) has long been recognized but the data on this adverse effect are limited. Methods To further characterize this possible association, we conducted a systematic review and meta-analysis of observation studies that reported odds ratio, relative risk, hazard ratio or standardized incidence ratio comparing risk of exacerbation of HF in patients with pre-existing HF who took NSAIDs versus non-users. Pooled risk ratios (RR) and 95% confidence intervals for conventional NSAIDs, celecoxib and rofecoxib were calculated using random-effect, generic inverse variance method. Results Six studies were identified and included in our data analysis. Use of conventional NSAIDs was associated with a significantly higher risk of development of exacerbation of HF with the pooled RR of 1.39 (95% CI 1.20-1.62). Elevated risk was also observed among celecoxib and rofecoxib users (RR 1.34, 95% CI 0.98-1.85 and RR 2.04, 95% CI 1.68-2.48). The pooled RR of rofecoxib was significantly higher than conventional NSAIDs (p = 0.02). Conclusion Use of NSAIDs is associated with an increased risk of HF exacerbation among patients with pre-existing HF. The excess risk was approximately 40% for conventional NSAIDs and celecoxib. The highest risk was observed among rofecoxib users.
ISSN: 18790828
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.